Anti-hypertension - Drug Pipeline Analysis and Market Forecasts to 2016

The Anti-hypertension Market Is Expected to Witness Steep Decline Due to the Patent Expiry of Blockbusters

Online PR News – 25-February-2010 – – GlobalData estimated the global anti-hypertension market in 2009 at $36.9 billion, indicating a compound annual growth rate (CAGR) of 5.3% between 2001 and 2009. The growth in the market can be mainly attributed to the growth in the sales of angiotensin renin blockers (ARB), the only therapeutic class that has antihypertensive drugs under patent protection. Though ARBs are less effective compared to other drugs such as beta-blockers (BBs, also known as beta-adrenergic receptor antagonists) and calcium channel blockers, they became the frontline treatment for patients diagnosed with hypertension. The prevalence of hypertension was another major factor responsible for the growth of anti-hypertension market between 2001 and 2009. Due to expected patent expiry of blockbusters such as Diovan, Cozaar and Avapro, the market is forecast to decline at a CAGR of -5.5% between 2009 and 2016.

For further details, visit:
Or please add this link to your browser:

GlobalData found that the current competition in the anti-hypertension market is very strong. The market in 2009 was dominated by ARBs such as Diovan, Atacand, Blopress and Avapro. In 2009, agents acting on the renin angiotensin system dominated the anti-hypertension market and they accounted for approximately 60% of the market. ARBs alone accounted for 42.6% of the global anti-hypertension market. Among the drugs approved for hypertension, diuretics are the most cost effective drugs. Despite the cost effectiveness and efficacy of diuretics, ARBs and Angiontensin converting enzyme (ACE) inhibitors are the most widely prescribed antihypertensive therapies in the market. In 2009, they accounted for approximately 30% to 40% of the global hypertension prescription volume. BBs were the second leading therapeutic class of drugs, accounting for approximately 30% of the global hypertension prescription volume. Diuretics were the third leading therapeutic class of drugs accounting for approximately 17% of the prescription volume.

For further details, visit:
Or please add this link to your browser:

GlobalData found that the approved treatment options for hypertension are very effective. Hypertension is a chronic disease and therefore patients use the drugs for many years. Patients tend to skip doses due to either forgetfulness or monotony. Skipping doses elevates the blood pressure (BP) and leads to hypertension again. Further, skipping doses also has a detrimental effect on the sales of the drugs. Therefore, any drug that can regulate BP for long durations will address the unmet needs.
The other major unmet need is the poor safety profiles. Clinical trial results on the antihypertensive drugs indicate that on an average 5% patients discontinued the study due to adverse effects. Any drug that can minimize the incidence of the side effects will become a promising drug in the anti-hypertension market.

GlobalData, the industry analysis specialist, has released a new report, “Anti-hypertension - Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global anti-hypertension market. The report identifies the key trends shaping and driving the dynamism in the global anti-hypertension market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-hypertension sector.

For further details, visit:
Or please add this link to your browser:

Or Visit our report store:

Contact Information
Rajesh Gunnam
Progressive House, Maidstone Road, Foots Cray, Sidcup
Kent London, DA14 5HZ